Our research indicates that quercetin, luteolin, epigallocatechin gallate and beta-sitosterol may be the primary active components of GJZLP, while protein targets such as IL6, TNF, JUN, TP53 and IL1B are potential targets for GJZLP in treating tuberculosis. This evidence concerns the gene IL1B and tuberculosis.